Therapeuticsmd Inc Revenue Growth Rates (TXMD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Therapeuticsmd Inc   (NASDAQ: TXMD)
 

TXMD's Revenue Growth by Quarter and Year

Therapeuticsmd Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TXMD/growth
https://api.csimarket.com/api/v1/companies/TXMD/fundamentals
https://api.csimarket.com/api/v1/companies/TXMD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TXMD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.26
2nd Quarter June 0.87
1st Quarter March 0.72
FY 2.85

TXMDs Annual Revenue
Therapeuticsmd Inc 's Revenue in the fiscal year 2025 $ 3.02 millions
Therapeuticsmd Inc 's Revenue in the fiscal year 2024 $ 1.76 millions
Therapeuticsmd Inc 's Revenue in the fiscal year 2023 $ 1.30 millions
Therapeuticsmd Inc 's Revenue in the fiscal year 2022 $ 69.96 millions
Therapeuticsmd Inc 's Revenue in the fiscal year 2021 $ 86.95 millions




TXMD Revenue third quarter 2026 Y/Y Growth Comment
Therapeuticsmd Inc achieved in the third quarter 2026, above Company average Revenue rise of 61.41% year on year, to $ 1.26 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue growth. While Therapeuticsmd Inc ' s Revenue jump of 61.41% ranks overall at the positon no. 766 in the third quarter 2026.


TXMD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 61.41 %
2nd Quarter June -8.42 %
1st Quarter March 84.62 %
FY   -

Financial Statements
Therapeuticsmd Inc 's third quarter 2026 Revenue $ 1.26 millions TXMD's Income Statement
Therapeuticsmd Inc 's third quarter 2025 Revenue $ 0.78 millions Quarterly TXMD's Income Statement


TXMD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.71 %
2nd Quarter June 20.83 %
1st Quarter March -19.1 %
FY (Year on Year)   -


Back to TXMD Growth rate Comparisons >> Back to TXMD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #163
Overall #766

Revenue Y/Y Growth Statistics
High Average Low
256.14 % 39.15 % -98.14 %
(Mar 31 2020)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #163
Overall #766
Revenue Y/Y Growth Statistics
High Average Low
256.14 % 39.15 % -98.14 %
(Mar 31 2020)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Therapeuticsmd Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
123767.45 % 2106.99 % -99.88 %
(Mar 31 2013)  


TXMD's III. Quarter Q/Q Revenue Comment
Therapeuticsmd Inc achieved in the III. Quarter 2026 below company average Revenue jump of 44.71% quarter on quarter, to $ 1.26 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -17.89% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Therapeuticsmd Inc 's Revenue growth quarter on quarter, overall rank is 500.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #99
Overall #500
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #99
Overall #500
Revenue Q/Q Growth Statistics
High Average Low
123767.45 % 2106.99 % -99.88 %
(Mar 31 2013)  


TXMD's III. Quarter Q/Q Revenue Comment
Therapeuticsmd Inc achieved in the III. Quarter 2026 below company average Revenue jump of 44.71% quarter on quarter, to $ 1.26 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -17.89% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Therapeuticsmd Inc 's Revenue growth quarter on quarter, overall rank is 500.


Therapeuticsmd Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3.27
Y / Y Revenue Growth (TTM) 45.59 %
Year on Year Revenue Growth Overall Ranking # 194
Seqeuential Revenue Change (TTM) -2.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 766


Cumulative Revenue growth Comment
Assuming the Therapeuticsmd Inc 's fiscal year would have ended in Jun 30 2026, Therapeuticsmd Inc would have reprted above average annual Revenue growth of 45.59% year on year, of $ 3 millions.
This marks a slow-down of the companys growth trends and from the 82.13% increase in Mar 31 2026.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 194, from total ranking in previous quarter at 363.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 53
Overall # 194

Revenue TTM Y/Y Growth Statistics
High Average Low
256.14 %
 39.15 %
-98.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 64
Sector # 163
S&P 500 # 766
Cumulative Revenue growth Comment
Assuming the Therapeuticsmd Inc 's fiscal year would have ended in Jun 30 2026, Therapeuticsmd Inc would have reprted above average annual Revenue growth of 45.59% year on year, of $ 3 millions.
This marks a slow-down of the companys growth trends and from the 82.13% increase in Mar 31 2026.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 194, from total ranking in previous quarter at 363.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 53
Overall # 194

Revenue TTM Y/Y Growth Statistics
High Average Low
256.14 %
39.15 %
-98.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 64
Sector # 163
S&P 500 # 766




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TXMD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions


About Therapeuticsmd Inc Revenue Growth Rates (TXMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Therapeuticsmd Inc (CIK 25743).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-087768
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Therapeuticsmd Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.